Learning the therapeutic targets of acute myeloid leukemia through multiscale human interactome network and community analysis

Abstract Acute myeloid leukemia (AML) is caused by proliferation of mutated myeloid progenitor cells. The standard chemotherapy regimen does not efficiently cause remission as there is a high relapse rate. Resistance acquired by leukemic stem cells is suggested to be one of the root causes of relaps...

Full description

Saved in:
Bibliographic Details
Main Authors: Suruthy Sivanathan, Ting Hu
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BioData Mining
Subjects:
Online Access:https://doi.org/10.1186/s13040-025-00444-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850270869777022976
author Suruthy Sivanathan
Ting Hu
author_facet Suruthy Sivanathan
Ting Hu
author_sort Suruthy Sivanathan
collection DOAJ
description Abstract Acute myeloid leukemia (AML) is caused by proliferation of mutated myeloid progenitor cells. The standard chemotherapy regimen does not efficiently cause remission as there is a high relapse rate. Resistance acquired by leukemic stem cells is suggested to be one of the root causes of relapse. Therefore, there is an urgency to develop new drugs for therapy. Repurposing approved drugs for AML can provide a cost-friendly, time-efficient, and affordable alternative. The multiscale interactome network is a computational tool that can identify potential therapeutic candidates by comparing mechanisms of the drug and disease. Communities that could be potentially experimentally validated are detected in the multiscale interactome network using the algorithm CRank. The results are evaluated through literature search and Gene Ontology (GO) enrichment analysis. In this research, we identify therapeutic candidates for AML and their mechanisms from the interactome, and isolate prioritized communities that are dominant in the therapeutic mechanism that could potentially be used as a prompt for pre-clinical/translational research (e.g. bioinformatics, laboratory research) to focus on biological functions and mechanisms that are associated with the disease and drug. This method may allow for an efficient and accelerated discovery of potential candidates for AML, a rapidly progressing disease.
format Article
id doaj-art-290970ca41ef489f9d3de1573dcc80fb
institution OA Journals
issn 1756-0381
language English
publishDate 2025-05-01
publisher BMC
record_format Article
series BioData Mining
spelling doaj-art-290970ca41ef489f9d3de1573dcc80fb2025-08-20T01:52:25ZengBMCBioData Mining1756-03812025-05-0118112710.1186/s13040-025-00444-xLearning the therapeutic targets of acute myeloid leukemia through multiscale human interactome network and community analysisSuruthy Sivanathan0Ting Hu1School of Computing and the Department of Biomedical and Molecular Sciences, Queen’s UniversitySchool of Computing, Queen’s UniversityAbstract Acute myeloid leukemia (AML) is caused by proliferation of mutated myeloid progenitor cells. The standard chemotherapy regimen does not efficiently cause remission as there is a high relapse rate. Resistance acquired by leukemic stem cells is suggested to be one of the root causes of relapse. Therefore, there is an urgency to develop new drugs for therapy. Repurposing approved drugs for AML can provide a cost-friendly, time-efficient, and affordable alternative. The multiscale interactome network is a computational tool that can identify potential therapeutic candidates by comparing mechanisms of the drug and disease. Communities that could be potentially experimentally validated are detected in the multiscale interactome network using the algorithm CRank. The results are evaluated through literature search and Gene Ontology (GO) enrichment analysis. In this research, we identify therapeutic candidates for AML and their mechanisms from the interactome, and isolate prioritized communities that are dominant in the therapeutic mechanism that could potentially be used as a prompt for pre-clinical/translational research (e.g. bioinformatics, laboratory research) to focus on biological functions and mechanisms that are associated with the disease and drug. This method may allow for an efficient and accelerated discovery of potential candidates for AML, a rapidly progressing disease.https://doi.org/10.1186/s13040-025-00444-xAcute myeloid leukemia (AML)DrugsTherapeutic targetsHuman interactomeNetworksCommunity detection
spellingShingle Suruthy Sivanathan
Ting Hu
Learning the therapeutic targets of acute myeloid leukemia through multiscale human interactome network and community analysis
BioData Mining
Acute myeloid leukemia (AML)
Drugs
Therapeutic targets
Human interactome
Networks
Community detection
title Learning the therapeutic targets of acute myeloid leukemia through multiscale human interactome network and community analysis
title_full Learning the therapeutic targets of acute myeloid leukemia through multiscale human interactome network and community analysis
title_fullStr Learning the therapeutic targets of acute myeloid leukemia through multiscale human interactome network and community analysis
title_full_unstemmed Learning the therapeutic targets of acute myeloid leukemia through multiscale human interactome network and community analysis
title_short Learning the therapeutic targets of acute myeloid leukemia through multiscale human interactome network and community analysis
title_sort learning the therapeutic targets of acute myeloid leukemia through multiscale human interactome network and community analysis
topic Acute myeloid leukemia (AML)
Drugs
Therapeutic targets
Human interactome
Networks
Community detection
url https://doi.org/10.1186/s13040-025-00444-x
work_keys_str_mv AT suruthysivanathan learningthetherapeutictargetsofacutemyeloidleukemiathroughmultiscalehumaninteractomenetworkandcommunityanalysis
AT tinghu learningthetherapeutictargetsofacutemyeloidleukemiathroughmultiscalehumaninteractomenetworkandcommunityanalysis